Table 1.
Demographics and baseline clinical characteristics of patients with metastatic clear cell renal cell carcinoma (n = 39) and sites of tissue collection (n = 58)
| Variable | Total |
|---|---|
| Median age at diagnosis, years | 56 (36–77) |
| Median follow‐up after diagnosis, months | 53 (6–177) |
| Median maximal tumor dimension, cm | 9·2 (2·5–16·2) |
| Gender | |
| Male | 24 |
| Female | 15 |
| Race | |
| White | 37 |
| Asian | 1 |
| Black | 0 |
| Other | 1 |
| Fuhrman nuclear grade | |
| 2 | 4 |
| 3 | 21 |
| 4 | 14 |
| Laterality | |
| Right | 24 |
| Left | 15 |
| pT † | |
| T1 | 3 |
| T2 | 7 |
| T3 | 25 |
| T4 | 4 |
| pN † | |
| N0 | 14 |
| N1 | 25 |
| pM † | |
| M0 | 15 |
| M1 | 24 |
| IMDC risk category* | |
| Favorable‐risk (0 criteria) | 0 |
| Intermediate‐risk (1–2 criteria) | 23 |
| Poor‐risk (≥ 3 criteria) | 16 |
| Immunotherapy courses received** | |
| Interleukin‐2 | 24 |
| Nivolumab | 10 |
| Pembrolizumab | 7 |
| Targeted therapy courses received** | |
| Pazopanib | 17 |
| Axitinib | 13 |
| Sorafenib | 13 |
| Sunitinib | 10 |
| Everolimus | 7 |
| Cabozantinib | 6 |
| Bevacizumab | 3 |
| Tissue specimen collection site | |
| Kidney | 28 |
| Skin/soft tissue | 4 |
| Retroperitoneum | 3 |
| Lung | 2 |
| Adrenal | 1 |
| Bone | 1 |
ccRCC = clear cell renal cell carcinoma; IMDC = International Metastatic RCC Database Consortium.
Pathological staging is based on the time of initial nephrectomy or metastasectomy. All patients in this study (n = 39) developed metastatic disease during their treatment course.
IMDC risk score is relevant to mRCC patients undergoing systemic therapy, and several ongoing trials are using this model in prospective studies. The criteria include: less than 1 year from time of diagnosis to systemic therapy, Karnofsky performance status < 80%, hemoglobin < lower limit of normal, calcium > upper limit of normal, neutrophil count > upper limit of normal and platelet count > upper limit of normal.
Includes types of therapy spanning from first‐ to fifth‐line treatments.